PERIPHERAL VASCULAR DEVICES MARKET ANALYSIS

Key Developments

• On March 04, 2024, BD (Becton, Dickinson and Company), a leading global medical technology company, announced the enrollment of the first patient in the "AGILITY" investigational device exemption (IDE) study, which will evaluate the safety and efficacy of the BD Vascular Covered Stent for the treatment of Peripheral Arterial Disease (PAD). The Vascular Covered Stent under investigation is a nitinol implant encased in polytetrafluoroethylene that self-expands and is low profile.
• On February 14, 2024, Efemoral Medical, a developer of advanced interventional bioresorbable therapies, announced that the U.S. Food & Drug Administration (FDA) had designated its novel Efemoral Vascular Scaffold System (EVSS) as a Breakthrough Device for the treatment of de novo or restenotic lesions of the infrapopliteal arteries in patients with Chronic Limb Threatening Ischemia (CLTI)
• In March 2023, Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced that the Shockwave L6 Peripheral IVL Catheter is now commercially available in the U.S., following U.S. FDA clearance. The Shockwave L6 catheter is designed to change calcification in major peripheral arterial lesions that would otherwise be difficult to treat, such as the iliac and common femoral arteries.
• In February 2023, Abbott, a medical device company, signed a definitive agreement to acquire Cardiovascular Systems, Inc., a medical device company that manufactures innovative atherectomy system used to treat peripheral and coronary artery disease. CSI is a market leader in atherectomy devices, a minimally invasive therapy for plaque buildup in arteries that can limit blood flow. The use of atherectomy in the procedure can assist maximize the effects of traditional balloon angioplasty or stent therapies in restoring blood flow in complicated arterial disease.